These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 36810856)

  • 21. Mechanisms of primary resistance to EGFR targeted therapy in advanced lung adenocarcinomas.
    Jin Y; Shi X; Zhao J; He Q; Chen M; Yan J; Ou Q; Wu X; Shao YW; Yu X
    Lung Cancer; 2018 Oct; 124():110-116. PubMed ID: 30268447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Small cell lung cancer transformation after EGFR-TKIs treatment in lung adenocarcinoma: A case report and literatures review.
    Chen X; Li D; Miao K; Shou T; Zhang W
    Medicine (Baltimore); 2023 Jan; 102(4):e32697. PubMed ID: 36705363
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reuse of osimertinib after small cell lung cancer transformation in lung adenocarcinoma with de-novo epidermal growth factor receptor T790M mutation: case report.
    Wang X; Liang J; Li L; Pan Z; Wang L
    Anticancer Drugs; 2023 Feb; 34(2):306-310. PubMed ID: 36206142
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic value of TP53 concurrent mutations for EGFR- TKIs and ALK-TKIs based targeted therapy in advanced non-small cell lung cancer: a meta-analysis.
    Qin K; Hou H; Liang Y; Zhang X
    BMC Cancer; 2020 Apr; 20(1):328. PubMed ID: 32299384
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetic alterations and protein expression in combined small cell lung cancers and small cell lung cancers arising from lung adenocarcinomas after therapy with tyrosine kinase inhibitors.
    Shi X; Duan H; Liu X; Zhou L; Liang Z
    Oncotarget; 2016 Jun; 7(23):34240-9. PubMed ID: 27145273
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Simultaneous Acquisition of T790M Mutation and SCLC Transformation during Targeted Therapy in EGFR-Mutated Lung Adenocarcinoma: A Rare Case Report.
    Yazaki T; Kimoto M; Minagawa A; Maruno T; Yamanaka M; Sonehara K; Hama M; Nakamura T; Kanda S; Hanaoka M; Hachiya T
    Am J Case Rep; 2024 Jun; 25():e943466. PubMed ID: 38822519
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Small cell lung cancer transformation and T790M mutation: complimentary roles in acquired resistance to kinase inhibitors in lung cancer.
    Suda K; Murakami I; Sakai K; Mizuuchi H; Shimizu S; Sato K; Tomizawa K; Tomida S; Yatabe Y; Nishio K; Mitsudomi T
    Sci Rep; 2015 Sep; 5():14447. PubMed ID: 26400668
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Small Cell Lung Cancer Derived from Adenocarcinoma with Mutant Epidermal Growth Factor Receptor Provides a Signature of Transcriptional Alteration in Tumor Cells.
    Tenjin Y; Nakamura K; Ishizuka S; Saruwatari K; Sato R; Tomita Y; Saeki S; Ichiyasu H; Fujii K; Ito T; Sakagami T
    Intern Med; 2019 Nov; 58(22):3261-3265. PubMed ID: 31292388
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Whole-exome sequencing explored mechanism of selpercatinib resistance in RET-rearranged lung adenocarcinoma transformation into small-cell lung cancer: a case report.
    Peng Y; Zheng Z; Zewen W; Yanan L; Mingyan Z; Meili S
    BMC Pulm Med; 2023 Dec; 23(1):492. PubMed ID: 38057798
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Small-cell lung cancer transformation from EGFR-mutant adenocarcinoma after EGFR-TKIs resistance: A case report.
    Jiang Y; Shou L; Guo Q; Bao Y; Xu X; An S; Lu J
    Medicine (Baltimore); 2021 Aug; 100(32):e26911. PubMed ID: 34397927
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Neuroendocrine transformation from EGFR/ALK-wild type or TKI-naïve non-small cell lung cancer: An under-recognized phenomenon.
    Chu X; Xu Y; Li Y; Zhou Y; Chu L; Yang X; Ni J; Li Y; Guo T; Zheng Z; Zheng Q; Yao Q; Li Y; Zhou X; Zhu Z
    Lung Cancer; 2022 Jul; 169():22-30. PubMed ID: 35609408
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Small cell lung cancer transformation from EGFR-mutated lung adenocarcinoma: A case report and literatures review.
    Liu Y
    Cancer Biol Ther; 2018 Jun; 19(6):445-449. PubMed ID: 29461911
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EGFR-Mutant SCLC Exhibits Heterogeneous Phenotypes and Resistance to Common Antineoplastic Drugs.
    Lin CA; Yu SL; Chen HY; Chen HW; Lin SU; Chang CC; Yu CJ; Yang PC; Ho CC
    J Thorac Oncol; 2019 Mar; 14(3):513-526. PubMed ID: 30521971
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A high number of co-occurring genomic alterations detected by NGS is associated with worse clinical outcomes in advanced EGFR-mutant lung adenocarcinoma: Data from LATAM population.
    Heredia D; Mas L; Cardona AF; Oyervides V; Motta Guerrero R; Galvez-Nino M; Lara-Mejía L; Aliaga-Macha C; Carracedo C; Varela-Santoyo E; Ramos-Ramírez M; Davila-Dupont D; Martínez J; Cruz-Rico G; Remon J; Arrieta O
    Lung Cancer; 2022 Dec; 174():133-140. PubMed ID: 36379126
    [TBL] [Abstract][Full Text] [Related]  

  • 35. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.
    Niederst MJ; Sequist LV; Poirier JT; Mermel CH; Lockerman EL; Garcia AR; Katayama R; Costa C; Ross KN; Moran T; Howe E; Fulton LE; Mulvey HE; Bernardo LA; Mohamoud F; Miyoshi N; VanderLaan PA; Costa DB; Jänne PA; Borger DR; Ramaswamy S; Shioda T; Iafrate AJ; Getz G; Rudin CM; Mino-Kenudson M; Engelman JA
    Nat Commun; 2015 Mar; 6():6377. PubMed ID: 25758528
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-Mutated Advanced NSCLC.
    Kim Y; Lee B; Shim JH; Lee SH; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K
    J Thorac Oncol; 2019 Feb; 14(2):193-202. PubMed ID: 30391576
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of non-small cell lung cancer transforming to small cell lung cancer and its response to EGFR-TKI: a case report.
    Fang G; Liu W; Shang Y; Huo R; Shi X; Wang Y; Li J
    Ann Transl Med; 2022 Jan; 10(2):115. PubMed ID: 35282065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Rapid increase of serum neuron specific enolase level and tachyphylaxis of EGFR-tyrosine kinase inhibitor indicate small cell lung cancer transformation from EGFR positive lung adenocarcinoma?
    Zhang Y; Li XY; Tang Y; Xu Y; Guo WH; Li YC; Liu XK; Huang CY; Wang YS; Wei YQ
    Lung Cancer; 2013 Aug; 81(2):302-5. PubMed ID: 23683536
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Histological transformation into SCLC: An important resistance mechanism of NSCLC upon immunotherapy.
    Zeng J; Ding X; Ding J; Wang X
    Front Immunol; 2023; 14():1275957. PubMed ID: 38022621
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer.
    Zhou H; Hu Y; Luo R; Zhao Y; Pan H; Ji L; Zhou T; Zhang L; Long H; Fu J; Wen Z; Wang S; Wang X; Lin P; Yang H; Wang J; Song M; Yi X; Yang L; Xia X; Guan Y; Fang W; Yang Y; Hong S; Huang Y; Li P; Zhang Y; Zhou N
    Nat Commun; 2021 Sep; 12(1):5431. PubMed ID: 34521849
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.